WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

A BASIC REVIEW ON XYLAZINE DRUG

Ms. Aishwarya Kamble[1], Nikhil Mabrukar[2], Prasanna Mendgule[3], Kuldip Patil[4], Varad Mathapati[5] , Ritesh Ghodake[6]

Department of Pharmacology, Lokmangal college of Pharmacy , Wadala , Solapur-413004

ABSTRACT:

Xylazine is potent veterinary sedative and analgesic medicine. These drugs belong to the α_2 adrenergic agonist. This drug discovered to induce sedation and muscle relaxation and pain relief in animal (Docketing) undergoing medical procedure for surgeries. It's important to note that xylazine is not approved for use in humans by Dixyrazine with titanyl is known as "Zombie Drug "and "Tran Dope".

INTRODUCTION:

Xylazine was first synthesized in 1962 by Bayer pharmaceutics. The reason of discovery which is Xylazine's has muscle relaxant property. During the discovery trials were terminated due to its severe hypotension and CNS depressant effect. Xylazine marketed as Rampun, Anased, Sedazine, Chonazine. Xylazine chemical structure related to Phenothiazine, Tricyclic Antidepressant and Clonidine. According to the drug and alcohol dependence journal Xylazine was involved in only 0.36% of overdose death in 2015 as reported by CNN.As of 2020Xlyazine was associated with 6%of overdose death majority occurring in Philadelphia, Manyland and Connecticut. Today's scenario 1gm of cocaine or 1.3gm of beast (heroin) comes under 200$.In the case of Xylazine,4000gm of Xylazine comes under some amount which is 200$.Well we know the human tendency that is human get shifted to less costly things (Xylazine).[1] [2]

How It Works's:

In CNS Dopamine and Norepinephrine Neurotransmitter was found. Dopamine and Norepinephrine stored in vesicle which is present in pre-synaptic neuron. When Dopamine or Norepinephrine releases these 2 neurotransmitters goes and bind α_1 receiver receptor hence, action produce. These 2-neurotransmitter released in large amount. These 2 neurotransmitters bind to α_2 receptor which is present at pre-synaptic site produce negative feedback. If person taken Xylazine plus fentanyl these 2 chemicals bind to α_2 receptor and stop the release and production of Dopamine and Norepinephrine hence the person gets stocked or hanged at particular position and they are not able to understand what is going to happen in their surrounding's Xylazine works as Vaso constrictor due to this O_2 is not supplied to the tissue result in drastic effect like skin perfusion.[3] [4]

XYLAZINE EFFECT IN ANIMAL:

Xylazine is preferred through Intramuscular or Intravenous route. It depends on the surgeon or PR actioner which route of administration to be preferred we need quicker and deep sedation then IV route is preferred as compare to IM route.

- Sedation: It induces sedation and relaxation in animals making the calmer and easier to handle.[5]
- Muscle Relaxation: It has muscle relaxant properties, which can be beneficial in procedures that requires immobilization or muscle relaxation.[4]
- Minimized Stress: When used appropriately Xylazine can help reduce stress and anxiety in animal. This is important for both the wellbeing of the animal and safety of veterinary staff.[5]
- Wide Veterinary Application: Xylazine is versatile and can be used in variety of veterinary settings including large animals like horses, cattle, deer as well as smaller animals like dogs, cats. It has application in surgery, diagnostic procedure and restraint.[5]
- Cost Effective: Compared to some other aesthetic agents Xylazine can be cost effective for sedating and managing pain in animal[5]

DISADVANTAGE:

- Respiratory Depression: It can cause respiratory depression in animal which means it can slow down rate and depth of breathing. This can be particularly problematic in animal with pre-existing respiratory condition or when used in high dose.[6]

- Cardiovascular Effect: It can lead to changes in hear rate and blood pressure. It often causes Bradycardia and hypotension. This effect can be harmful especially in animals with heart or circulatory issues.[6]

- Profound Sedation: While sedation is a desired effect in many cases the profound sedation induced Xylazine can be disadvantage if the animal needs to be alert or responsive during procedure.[7]

- Limited Analgesia: While Xylazine provide some analgesia it may not be sufficient for more painful procedure .In such cases, additional analgesics or anaesthetics may be required potentially increasing the complexity of the anaesthesia protocol.[7]

- Risk of Overdose: Xylazine has a narrow therapeutic window meaning the difference between a safe and an overdose can be small. Careful dosing and monitoring are crucial to avoid overdosing. Which can lead to severe respiratory and cardiovascular effects.[8]

- Recovery Time: Animals sedated with Xylazine may experience a longer recovery time compared to lighter sedative. This can be problematic if quicker recovery is needed for the animal's wellbeing for logistical reasons.[8]

REFERENCE:

1. Grewal A. Xylazine: a review of its pharmacology and toxicology in animals. Vet Hum Toxicol. 1989;31(6):516–519.
2. Ruiz-Colón K, Chavez-Arias C, Diaz-Alcala JE, Martinez MA, Martinez MA. Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: a comprehensive review of the literature. Forensic Sci Int. 2014;240:1–8.
3. United States Drug Enforcement Administration. The Growing Threat of Xylazine and its Mixture with Illicit Drugs. DEA Diversion Control Division. 2022.
4. Torruella RA. Xylazine (veterinary sedative) use in Puerto Rico. Subst Use Misuse. 2011;46(5):664–667.
5. U.S. Centers for Disease Control and Prevention (CDC). Notes from the Field: Xylazine-Related Deaths - Cook County, Illinois, 2017-2021. MMWR Morb Mortal Wkly Rep. 2022;71(3):84–87.
6. Jones CM, Compton WM, Mustaquim D. Patterns and Characteristics of Methamphetamine Use Among Adults — United States, 2015–2018. MMWR Morb Mortal Wkly Rep. 2020;69(12):317–323.
7. Johnson B, Richert A, Lamy FR, Carrico AW. Emerging health threats of xylazine. Int J Drug Policy. 2023;112:103999.
8. Dyer JE, Boyer EW, Williams KA. Xylazine toxicity in humans. Am J Emerg Med. 2004;22(2):87–88.